Objective—To determine effects of selegiline
hydrochloride, phenylpropanolamine (PPA), or a combination
of both on physiologic and behavioral variables
Animals—40 adult hound-type dogs.
Procedure—Dogs were assigned to 4 groups. One
group received selegiline (1 mg/kg, PO, q 24 h) and
PPA (1.1 mg/kg, PO, q 8 h), a second group received
selegiline alone, a third group received PPA alone, and
a fourth group received neither drug. Dogs were
observed 3 times/d throughout the 30-day study (daily
during the first week, on alternate days during the
next 2 weeks, and again daily during the final week).
Observers recorded rectal temperature, pulse, respiratory
rate, oscillometric blood pressure, and lead-II
ECG and assessed 4 behaviors, using an analogue
scale. Variables were compared among treatment
groups by use of a 2-factor ANOVA with data categorized
into three 10-day treatment periods. A similar
comparison was made among treatment groups with
data categorized by time of observation (morning,
afternoon, or evening) for all study days.
Results—Variables did not differ among groups at
study initiation. Pulse rate was the only variable that
differed significantly among treatment groups during
the study. During the first 10 days of treatment, dogs
receiving PPA had a lower pulse rate than dogs that
did not. Although signs of illness were apparent in a
few dogs, illness did not appear to be related to treatment.
Conclusion and Clinical Relevance—Adverse
effects were not detected after administration of
selegiline, PPA, or a combination of the drugs in
healthy dogs. (Am J Vet Res 2002;63:827–832)
Objective—To examine buffy coat smears for circulating mast cells in clinically normal cats and cats with illnesses unrelated to mast cell tumors and identify whether conditions other than mast cell tumors are associated with mastocytemia in cats.
Animals—40 clinically normal cats and 40 cats with diseases unrelated to mast cell tumors (all cats were client owned).
Procedures—A blood sample for a CBC, serum biochemical analyses, and buffy coat evaluation was obtained from each cat. Ill cats underwent other testing on the basis of their disease process.
Results—No mast cells were detected in any sample. Eosinophilia was evident in 11 (27.5%) and 12 (30%) clinically normal and ill cats, respectively. Basophilia was identified in 4 (10%) and 8 (20%) clinically normal and ill cats, respectively. Eight of the 40 (20%) ill cats had neutrophilia.
Conclusions and Clinical Relevance—Circulating mast cells were not identified in clinically normal cats or ill cats without mast cell tumor–related disease. Ill cats did have conditions that caused eosinophilia, basophilia, or neutrophilia. The absence of mast cells in buffy coats obtained from clinically normal and ill cats lends support to the current practice of buffy coat evaluation for tumor staging and follow-up examinations in cats with mast cell tumors. Further studies of buffy coat analysis in cats with different forms of mast cell tumors are indicated to specifically elucidate the test's prognostic value for those patients.
To evaluate whether concurrent analysis of CSF samples from 2 collection sites (cerebellomedullary cistern [CMC] and lumbar subarachnoid space [LSS]) versus only 1 site could improve the diagnostic sensitivity of CSF analysis for dogs with suspected steroid-responsive meningitis arteritis (SRMA).
111 client-owned dogs with SRMA diagnosed at 3 veterinary referral hospitals between 2011 and 2017.
Only dogs with CSF collected from both sites (CMC and LSS) and with no previous history of corticosteroid administration were included. Medical record data and logistic regression were used to identify factors associated with having a total nucleated cell concentration (TNCC) within the reference interval in a CSF sample from 1 collection site.
The TNCC was within the reference interval (TNCC < 5 cells/μL) in the CSF sample from 1 collection site for 8 of 111 (7%) dogs and was only slightly high (TNCC, 5 to 9 cells/μL) in the sample from 1 or both sites for 10 (11%) other dogs. For each of these 18 dogs, results for samples from 1 site were consistent with SRMA. The proportion of CSF samples that had a TNCC within the reference interval was comparable between sites. As age increased, so did the risk of having an unremarkable TNCC in the CSF sample from 1 site, albeit only slightly (OR, 1.08; 95% confidence interval, 1.01 to 1.16).
CONCLUSIONS AND CLINICAL RELEVANCE
CSF samples from both the CMC and LSS should be analyzed when evaluating dogs with suspected SRMA to improve the chance of detecting a high TNCC.